Firefly Neuroscience Inc. is a medical technology and artificial intelligence company that develops neuroscientific software solutions to improve brain health outcomes for patients with neurological and mental disorders. Its flagship offering, the FDA-510(k) cleared Brain Network Analytics (BNA™) platform, uses AI and machine learning to analyze standardized electroencephalogram (EEG) and event-related potential (ERP) data from rest and cognitive tasks. This technology compares individual brain activity patterns to a proprietary normative database, providing objective measures of functional brain networks and cognitive performance to support diagnosis and treatment monitoring for conditions including depression, dementia, anxiety disorders, concussions, and ADHD. Firefly Neuroscience Inc. also provides the CLEAR Platform, a preprocessing tool that enhances EEG data quality by removing artifacts using advanced signal processing and NVIDIA GPU acceleration. The company serves pharmaceutical and medtech firms for drug research and clinical trials, as well as medical practitioners and clinics. It maintains collaborations with academic institutions and partners in neuroscience research. Founded in 2006 and headquartered in Kenmore, New York, Firefly Neuroscience Inc. operates primarily in North America with a focus on its BNA platform segment.